Abstract
Introduction: Since new antiretroviral therapy (HAART) introduction in HIV patients there was an increase of AIDS non-defining cancers incidence, like lung cancer.
Objectives: Characterize patients diagnosed with primary lung cancer and HIV followed at Oncologic Pneumonology and Immunodeficiency appointments at Faro Hospital.
Method: Analytical, cross-sectional, retrospective study of these patients followed at these appointments from 01/01/2011 to 31/12/2015.
Results: From the 644 new cases of lung cancer diagnosed at the considered time interval, 10 patients were HIV positive (1,6%). They were all male 50 years old mean age, all with smoking habits history (49 mean pack year), HIV1 infection (50% had AIDS criteria) and used HAART, 60% had history of intravenous drug use. 30% had COPD and 20% had recurrent respiratory infections. CD4 T-cells count average at diagnosis was 329/mm3. 60% had CD4 T-cells>200/mm3. The most frequent histologic diagnose was Adenocarcinoma and Squamous Cell Carcinoma. At diagnosis time, cancer stage was usually advanced (70% at stage IV), so 50% had first-line chemotherapy, 20% first-line combined chemoradiation and just 10% had combined chemoradiation with surgery and adjuvant chemotherapy, the others had palliative radiation and support treatment. Average survival was 17,88 months and 70% died (10% were lost at the follow-up). Average survival of patients with CD4 T-cells<200/mm3 was 2,35 months and those with CD4 T-cells>200/mm3 was 15,85 months (p value=0.05).
Conclusions: Male gender with smoking habits history prevailed. At diagnosis, cancer was usually at IV stage, being adenocarcinoma and squamous cell carcinoma the most common diagnosis. CD4 T-cells>200/mm3 was associated to a superior survival average.
- Copyright ©the authors 2017